Gilead公司需要证明公民身份在贫穷国家购买Sovald

StephenW

Gilead to require proof of citizenship to buy Sovaldi in poor countries
Group says big brother tactics may keep patients from getting hep C drugs
March 18, 2015 | By Eric Palmer


Not long after Gilead Sciences' ($GILD) high-priced hep C superdrugs Sovaldi, and then combo drug Harvoni, hit the market, the California drugmaker struck deals with 11 generic drugmakers to make cut-rate versions available, and affordable, in 91 developing countries. But Gilead is not as generous as it might seem, Doctors Without Borders claims. It says Gilead has loaded up production agreements with nefarious requirements to milk it for profits, provisions that will make it hard, if not impossible, for some infected people to get the drug that could cure them.


Médecins Sans Frontières/Doctors Without Borders (MSF) is urging Gilead ($GILD) to drop some of the provisions. If Gilead won't, MSF suggests that generic drugmakers ignore some of the requirements, like demanding that patients provide proof of citizenship to fill a prescription.

"We're seeing Gilead trying everything it can to squeeze every last drop of profit out of some middle-income and high-burden countries, and millions of people with hepatitis C will have to pay the price," said Rohit Malpani, of MSF.


A spokesperson for Gilead could not be reached today. The drugmaker has been lambasted in the U.S. for putting a retail price of $85,000 on Sovaldi and of about $94,000 on Harvoni, prices that have allowed Gilead to make back tens of billions of dollars on the medications in the first year on the market. They are a bit cheaper in Europe where regulators demanded it and Gilead is using tiered pricing in other countries depending on their economic profile. Fifty middle income countries will pay less than high-income countries but more than the 91 low-income countries, for example.

But MSF says to rake in the most it absolutely can, Gilead's licenses with the generic drugmakers make them demand that health providers put very tight controls on their sales. They must require patients to prove citizenship and residency to get their prescription filled. That, MSF says, is to prevent anyone from countries where the hep C drugs will be priced higher--countries like China, Thailand and Argentina--from buying cheaper versions of the drug in a low-cost country. Besides the fact that demanding papers may violate patient confidentiality, it could exclude anyone like immigrants with hep C from getting treatment, or even just poor people who don't have papers, the organization claims.

When IDs are provided, they will be used to put an identifying barcode on the bottles they receive with their name and other info. Not only can the code be used to guarantee only residents of the country get the drugs, Gilead is using the barcode track its sales and use and the agreements allow Gilead to use that patient information any way it chooses. While the barcode can be read with a smartphone, the group does not address the potential issues around how developing countries, where meds may be dispensed in remote areas, will be able to administer all of the provisions.

The provisions require that patients then return a bottle to get a new bottle and allows them to get only one bottle of their prescription at a time, even though allowing them to get multiple bottles could "ease the burden on patients and health providers," MSF says.

The licenses are for 5 years and those who sign can't get out of them, even if a country they produce it for allows unrestricted sales of generics. In fact, India has rejected Gilead's patent but as MSF reads the agreement, the Indian drugmakers that have signed up would be prevented from selling cheaper versions there without the restrictions. MSF thinks Gilead is trying to lock all of these restrictions in now, ahead of any losing a patent fight in any country, to maximize its profits.

"We've never seen anything like Gilead's anti-diversion programme before, where a company can potentially violate patient confidentiality and compromise treatment outcomes in order to protect its profits," said Dr. Manica Balasegaram, executive director of MSF's Access Campaign. "Gilead is forcing medical providers to introduce policing measures that could lead to dangerous treatment interruption for patients."

- here's the MSF release

Related Articles:
Gilead's Sovaldi, Harvoni push its full-year sales to $25B; earnings beat expectations
Gilead's Sovaldi the latest casualty in India's patent crusade
Gilead to offer cheap Sovaldi to 80 countries
Gilead Sciences prices Sovaldi in India at a tiny fraction of U.S. cost

StephenW

Gilead公司需要证明公民身份在贫穷国家购买Sovaldi
集团表示，大哥的战术可能使患者获不能得丙肝药物
2015年3月18日|由埃里克·帕尔默


没过多久吉利德科学公司（GILD $）高价丙肝superdrugs Sovaldi，再组合药物Harvoni，冲击市场，加州制药公司达成的交易有11通用制药商做出削减率版本，而且价格适中，在91发展中国家。但吉利德并不慷慨，因为它看起来，无国界医生组织索赔。它说，吉利德已经加载了生产协议与邪恶的要求，以牛奶它的利润，规定，这将使它很难，如果不是不可能的，对一些感染者获得，可以治愈他们的药物。


无国界/无国界医生组织（MSF）正在敦促吉利德（$ GILD）下降的一些规定。如果吉利德不会，无国界医生建议，一般的制药商忽略了一些要求，如要求病人提供公民身份的证明去抓药。

“我们看到吉利德尝试一切可能挤压利润的每一滴出一些中等收入和高负担国家，数以百万计的人患有丙型肝炎将不得不付出的代价，”无国界医生说的罗希特Malpani， 。


一位发言人吉利德无法走到今天。该制药商已经骂得狗血淋头在美国穿上Sovaldi 85,000美元零售价约为94000美元上Harvoni，已经让吉利德做回几十对药物的数十亿美元的第一年，市场上的价格。他们有点便宜在欧洲，监管部门的要求，并Gilead公司使用分层定价在其他国家根据自己的经济状况。五十中等收入国家将支付比高收入国家低于91低收入国家较少，但更多的，例如。

不过，无国界医生说，在大多数IT绝对可以，Gilead公司牌照与一般的制药商使他们的需求放在非常严格控制对他们的销售的医疗服务提供者耙。他们必须要求病人来证明公民身份和居住，以获得他们的药方上的药。也就是说，无国界医生说，这是为了防止所在国家的丙肝药物的价格将高于任何人 - 国家，如中国，泰国和阿根廷 - 从买便宜版本的药物在低成本国家。另外一个事实，即要求苛刻的论文可能违反病人保密，它可以排除有人像移民与丙肝的治疗得到，甚至只是可怜的人谁没有论文，组织索赔。

当被提供的ID，它们将被用来把一个识别条形码上它们接收与他们的名称和其他信息的瓶。不仅可以在代码中使用，以保证该国唯一的居民拿到药品，Gilead公司正在使用的条形码追踪其销售和使用，该协议允许Gilead公司使用该患者信息的任何方式，它选择。而条形码可以读取用智能手机，该集团并没有解决各地发展中的国家，在那里吃药可以在偏远地区进行分配，怎么就能管理所有的规定，潜在的问题。

该规定要求患者再回到瓶子得到一个新瓶，并允许他们只得到一瓶其处方的时间，即使让他们得到多瓶可以“减轻患者和医疗服务提供者的负担，”无国界医生说。

该许可证为5年和那些谁签署出不来他们，即使他们产生它的国家允许无限制的销售仿制药。事实上，印度已经拒绝了吉利德公司的专利，但作为MSF读取协议，已签署了印度制药公司将出售更便宜的版本有没有限制，是可以避免的。无国界医生认为，吉利德正试图锁定在目前所有的这些限制，提前在任何国家任何失去专利斗争，以实现利润​​最大化。

“我们从来没有见过这样吉利德的抗分流方案前，在一家公司有可能侵犯病人隐私和妥协治疗效果，以保护其利润的东西，”马尼卡Balasegaram博士，无国界医生的访问活动执行董事说。 “基列迫使医疗机构推行的警务措施，可能导致危险的中断治疗的患者。”

- 这里的MSF发布

相关文章：
Gilead公司Sovaldi，Harvoni推动其全年销售额为250亿美元;盈利超预期
Gilead公司Sovaldi最新的伤亡在印度的专利讨伐
Gilead公司提供廉价的Sovaldi至80个国家
Gilead Sciences公司的价格Sovaldi在印度的美国成本的一小部分